Compare Abeona Therapeutics Inc (ABEO) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Funko Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Funko Inc trades at $5.86 (market cap $332.33M). The key difference: Abeona Therapeutics Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Funko Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | FNKO | |
|---|---|---|
Market Cap | $421.19M | $332.33M |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $6.35 |
52-Week Low | $4.17 | $2.65 |
Enterprise Value | $276.10M | $552.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
Funko (FNKO) trades at $6.19, up 5.27% with bullish technical signals and strong recent earnings beats. The company shows improving fundamentals with Q2 2026 revenue growth of 7% to $207.7 million and raised EBITDA guidance. Despite negative net margins, the stock trades at attractive valuation multiples with P/S of 0.35 and EV/EBITDA of 6.46. Recent management changes and successful product launches support positive momentum.
Outlook remains cautiously optimistic with analyst consensus leaning toward hold/buy. Key opportunities include continued execution of the 'Make Culture POP!' strategy and margin improvement, while risks include persistent negative profitability and competitive pressures in the collectibles market. The stock presents value potential if operational improvements continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
